1. Home
  2. News
  3. PYC Therapeutics Limited
  4. US FDA Grants Orphan Drug Designation to PYC Drug Candidate
More PYC Therapeutics Limited news
PYC Therapeutics LimitedASX: PYC

US FDA Grants Orphan Drug Designation to PYC Drug Candidate

Oct 20, 2024 at 9:55 PM EDT · Issued by PYC Therapeutics Limited

Filed with ASX · Oct 20, 2024 at 9:55 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/us-fda-grants-orphan-drug-designation-to-pyc-drug-candidate

PYC Therapeutics Limited on 6ix

Earlier from PYC Therapeutics

  • Notice of Annual General Meeting/Proxy FormOct 14, 2024
  • FDA Grants Rare Pediatric Disease Designation to PYC-001Aug 29, 2024
  • Appendix 4E and Audited Financial StatementsAug 29, 2024
  • PYC to Start Human Trials in Second Blinding Eye DiseaseAug 14, 2024
  • Visual Improvement in Multiple RP11 PatientsAug 11, 2024

Later from PYC Therapeutics

  • Interim Update on Progress in RP11 Repeat Dose TrialsOct 21, 2024
  • First ADOA Patient Dosed in Clinical TrialOct 31, 2024
  • RP11 SRC Approves Dose Escalation to Final Patient CohortNov 4, 2024
  • Consolidation/Split - PYCNov 11, 2024
  • PYC to Progress Kidney Drug Candidate Into Human TrialsNov 26, 2024
All PYC Therapeutics news releases↗

Follow PYC Therapeutics into a list and get an email when it puts out news.

Follow PYC Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer